IL5 and common cold: In fact, real life studies documented a significant improvement in quality of life, respectively assessed by SNOT-22 or Rhinosinusitis Outcomes Measure-31 (RSOM-31) after 6 and 12 months of treatment with the anti-IL5 [22–26].